Elvina Almuradova, Ambassador at European School of Oncology, shared on X about recent paper by Andrea Cercek et al. published in New England Journal of Medicine:

“In early-stage dMMR cancers, neoadjuvant PD-1 blockade achieved 92% 2-year recurrence-free survival – many patients avoided surgery. A new era in organ preservation!”

Nonoperative Management of Mismatch Repair–Deficient Tumors

Authors: Andrea Cercek et al.

Elvina Almuradova

Read insight on OncoDaily to explore more about dMMR:

“Organ Preservation in dMMR Tumors: Results from Neoadjuvant Phase II Study with Dostarlimab”

Elvina Almuradova: A new era in organ preservation

“In early-stage dMMR cancers, neoadjuvant PD-1 blockade achieved 92% 2-year recurrence-free survival – many patients avoided surgery. A new era in organ preservation!”